Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach
- Address
- lock Available on a paid plan
Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego - Advanced Clinical Research Center
The Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach is a leading academic medical center conducting cutting-edge clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology, metabolic disorders, and rare autoimmune conditions, with a strong focus on novel immunotherapy approaches and precision medicine.
- Advanced oncology trials including biliary tract cancer, gastric adenocarcinoma, non-small cell lung cancer, and head and neck squamous cell carcinoma with emphasis on targeted therapies and immunotherapy combinations
- Metabolic and hepatic disease research, particularly in non-alcoholic steatohepatitis (NASH/MASH), primary biliary cholangitis, primary sclerosing cholangitis, and chronic kidney disease
- Rare autoimmune and ophthalmologic conditions including thyroid eye disease, myasthenia gravis, and age-related macular degeneration with geographic atrophy
- Perioperative medicine and cardiovascular prevention, including surgical site infection prevention, myocardial injury prevention, and heart failure risk reduction
The center's comprehensive research portfolio encompasses Phase I through Phase III trials, demonstrating capability in early-stage drug development as well as large-scale pivotal studies. Special areas of innovation include gene therapy approaches for frontotemporal dementia, novel therapeutic strategies for carcinoid syndrome and refractory status epilepticus, and advanced weight management interventions. The facility's participation in international multicenter trials and its expertise in complex patient populations positions it as a key contributor to advancing medical science and improving patient outcomes across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 11 therapeutic areas and 15 of 71 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 69 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1AstraZeneca AB2active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus | Marinus Pharmaceuticals Inc. | Phase III | Not Recruiting | Nov 2023 | Apr 2024 |
IMP list
lock Showing 1 of 71 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Durvalumab | 4 | Unknown | 2019-04-23 | 2026-06-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.